Acquiring Company
Agomab
Acquired Company
Origo Biopharma
AntwerpenGhentBiotechnologyHealth CareScience And EngineeringDescription
Agomab Therapeutics NV (‘Agomab’) announced today that it has entered into a definitive agreement under which it will acquire Origo Biopharma S.L., a Spanish clinical-stage biotechnology company developing organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway for the treatment of fibrosis-related disorders. The combined organization will focus on translating growth factor signaling pathways into innovative therapies. Agomab’s hepatocyte growth factor (HGF)-targeting monoclonal antibodies together with Origo’s small molecule programs create a rich clinical pipeline of therapeutics that address fibrosis and organ failure in multiple therapeutic areas.
Quick answer
Agomab is acquiring Origo Biopharma, announced October 28, 2021. Agomab is based in Antwerpen, Antwerp, Belgium.
- How much did Agomab pay for Origo Biopharma?
- The deal value was not disclosed.
- What does Agomab do?
- Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function.
- Where are Agomab and Origo Biopharma based?
- Agomab is based in Antwerpen, Antwerp, Belgium. Origo Biopharma is based in Ghent, East Flanders, Belgium.
- Who are the decision-makers at Agomab?
- Fundz holds 1 contact at Agomab. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Science And Engineering and Biotechnology
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Strongbridge Biopharma Plc Announces Court Hearing Date To Approve Proposed Acquisition By Xeris Pharmaceuticals, Inc. (September 23, 2021)
- Labcorp Completes Acquisition Of Myriad Autoimmune’S Vectra Testing Business (September 13, 2021)
- Labcorp Completes Acquisition Of Myriad Autoimmune’S Vectra Testing Business (September 13, 2021)
- 23Andme Announces The Closing Of Its Acquisition Of Lemonaid Health (November 1, 2021)
- Ilumivu Announces Acquisition Of Cardiogram And Series A Investment Round To Accelerate Personalized Decision Support Solutions For Healthcare (October 21, 2021)
- Enveric Biosciences Announces Closing Of Magicmed Industries Acquisition (September 18, 2021)
Who to call at Agomab, and when
When Agomab changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Agomab raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Agomab, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Agomab. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Agomab makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Origo Biopharma?
Origo Biopharma was acquired by Agomab, based in Antwerpen. The deal was reported on October 28, 2021. Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Agomab is privately held and operates in Biotechnology.
When did Agomab acquire Origo Biopharma?
Agomab's acquisition of Origo Biopharma was reported on October 28, 2021. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Origo Biopharma do?
Origo Biopharma is the company acquired in this transaction. It is privately held, and is based in Ghent.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.